Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

Journal of Cellular Physiology

Volumn 234, Issue 5, 2019, Pages 5628-5642

  Abdollahpour Alitappeh, Meghdad ^a,b   Lotfinia, Majid ^c   Gharibi, Tohid ^d,e   Mardaneh, Jalal ^f   Farhadihosseinabadi, Behrouz ^c   Larki, Pegah ^c   Faghfourian, Babak ^g   Sepehr, Koushan Sineh ^h   Abbaszadeh Goudarzi, Kazem ⁱ   Abbaszadeh Goudarzi, Ghasem ^j,k   Johari, Behrooz ^l   Zali, Mohammad Reza ^c   Bagheri, Nader ^m  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LARESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f GONABAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ SABZEVAR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j SHAHROUD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^k SHAHROUD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^l ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^m SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

antibody drug conjugate; conjugation; cytotoxic small molecules; linkers; monoclonal antibody

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTIMITOTIC AGENT; BRENTUXIMAB VEDOTIN; CYTOTOXIC AGENT; INOTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; ANTIBODY CONJUGATE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

BYSTANDER EFFECT; CANCER THERAPY; CLINICAL OUTCOME; CYTOTOXICITY; DRUG CONJUGATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HISTORY; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PATIENT SAFETY; RISK ASSESSMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; PATIENT SAFETY; RISK ASSESSMENT;

EID: 85057242645     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.27419     Document Type: Review

References (121)

1. Abdollahpour-Alitappeh, M., Hashemi Karouei, S. M., Lotfinia, M., Amanzadeh, A., & Habibi-Anbouhi, M. (2018). A developed antibody–drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line. Artificial Cells, Nanomedicine, and Biotechnology, 1–8. https://www.tandfonline.com/doi/abs/10.1080/21691401.2018.1449119?journalCode=ianb20
2. Abdollahpour-Alitappeh, M., Lotfinia, M., Razavi-Vakhshourpour, S., Jahandideh, S., Najminejad, H., Sineh Sepehr, K., … Abolhassani, M. (2017). Evaluation of factors influencing antibody reduction for development of antibody drug conjugates. Iranian Biomedical Journal, 21(4), 270–274.
3. Acchione, M., Kwon, H., Jochheim, C. M., & Atkins, W. M. (2012). Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody–drug conjugates. mAbs, 4(3), 362–372.
4. Aires da Silva, F., Corte-Real, S., & Goncalves, J. (2008). Recombinant antibodies as therapeutic agents: Pathways for modeling new biodrugs. BioDrugs, 22(5), 301–314.
5. Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M., Law, C. L., Senter, P. D., & Benjamin, D. R. (2009). The pharmacologic basis for antibody–auristatin conjugate activity. Journal of Pharmacology and Experimental Therapeutics, 330(3), 932–938.
6. Almagro, J. C., & Fransson, J. (2008). Humanization of antibodies. Frontiers in Bioscience, 13, 1619–1633.
7. Al-Salama, Z. T. (2018). Inotuzumab ozogamicin: A review in relapsed/refractory B-cell acute lymphoblastic leukaemia. Targeted Oncology, 13, 525–532.
8. Bakhtiar, R. (2016). Antibody drug conjugates. Biotechnology Letters, 38(10), 1655–1664.
9. Bander, N. H. (2013). Antibody–drug conjugate target selection: Critical factors. Methods in Molecular Biology, 1045, 29–40.
10. Beck, A., Senter, P. D., & Chari, R. J. (2011). World antibody drug conjugate summit Europe: February 21–23, 2011; Frankfurt, Germany. mAbs, 3(4), 331–337.
11. Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology, 10(5), 345–352.
12. Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews. Drug Discovery, 16(5), 315–337.
13. Bhattacharyya, B., & Wolff, J. (1977). Maytansine binding to the vinblastine sites of tubulin. FEBS Letters, 75(1), 159–162.
14. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., … Zardi, L. (2002). Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. International Journal of Cancer, 102(1), 75–85.
15. Borvak, J., Richardson, J., Medesan, C., Antohe, F., Radu, C., Simionescu, M., … Ward, E. S. (1998). Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. International Immunology, 10(9), 1289–1298.
16. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., … Pazdur, R. (2001). Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7(6), 1490–1496.
17. Burris, H. A., 3rd, Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., … O’Shaughnessy, J. A. (2011). Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. Journal of Clinical Oncology, 29(4), 398–405.
18. Carter, P. J., & Senter, P. D. (2008). Antibody–drug conjugates for cancer therapy. Cancer Journal, 14(3), 154–169.
19. Casi, G., & Neri, D. (2012). Antibody–drug conjugates: Basic concepts, examples and future perspectives. Journal of Controlled Release, 161(2), 422–428.
20. Chalouni, C., & Doll, S. (2018). Fate of antibody–drug conjugates in cancer cells. Journal of Experimental & Clinical Cancer Research, 37(1), 20.
21. Chari, R. V. (1998). Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Advanced Drug Delivery Reviews, 31(1-2), 89–104.
22. Chari, R. V. (2008). Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Accounts of Chemical Research, 41(1), 98–107.
23. Chari, R. V., Miller, M. L., & Widdison, W. C. (2014). Antibody–drug conjugates: An emerging concept in cancer therapy. Angewandte Chemie (International Edition in English), 53(15), 3796–3827.
24. Conner, S. D., & Schmid, S. L. (2003). Regulated portals of entry into the cell. Nature, 422(6927), 37–44.
25. Damelin, M., Zhong, W., Myers, J., & Sapra, P. (2015). Evolving strategies for target selection for antibody–drug conjugates. Pharmaceutical Research, 32(11), 3494–3507.
26. de Goeij, B. E., Satijn, D., Freitag, C. M., Wubbolts, R., Bleeker, W. K., Khasanov, A., … Parren, P. W. (2015). High turnover of tissue factor enables efficient intracellular delivery of antibody–drug conjugates. Molecular Cancer Therapeutics, 14(5), 1130–1140.
27. DeVita, V. T., Jr., & Chu, E. (2008). A history of cancer chemotherapy. Cancer Research, 68(21), 8643–8653.
28. Dijoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L., Kunz, A., Boghaert, E. R., … Damle, N. K. (2007). CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunology and Immunotherapy, 56(7), 1107–1117.
29. Donaghy, H. (2016). Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody–drug conjugates. mAbs, 8(4), 659–671.
30. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., … Senter, P. D. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology, 21(7), 778–784.
31. Dosio, F., Brusa, P., & Cattel, L. (2011). Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins (Basel), 3(7), 848–883.
32. Dudley, A. C. (2012). Tumor endothelial cells. Cold Spring Harbor Perspectives in Medicine, 2(3), a006536.
33. Dumontet, C., & Jordan, M. A. (2010). Microtubule-binding agents: A dynamic field of cancer therapeutics. Nature Reviews. Drug DIscovery, 9(10), 790–803.
34. Elias, D. J., Hirschowitz, L., Kline, L. E., Kroener, J. F., Dillman, R. O., Walker, L. E., … Timms, R. M. (1990). Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Research, 50(13), 4154–4159.
35. Endo, N., Takeda, Y., Kishida, K., Kato, Y., Saito, M., Umemoto, N., & Hara, T. (1987). Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody. Cancer Immunology and Immunotherapy, 25(1), 1–6.
36. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., … Blättler, W. A. (2006). Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Research, 66(8), 4426–4433.
37. Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010). Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody–maytansinoid conjugates. Bioconjugate Chemistry, 21(1), 84–92.
38. Feld, J., Barta, S. K., Schinke, C., Braunschweig, I., Zhou, Y., & Verma, A. K. (2013). Linked-in: Design and efficacy of antibody drug conjugates in oncology. Oncotarget, 4(3), 397–412.
39. Ferl, G. Z., Kenanova, V., Wu, A. M., & DiStefano, J. J., 3rd (2006). A two-tiered physiologically based model for dually labeled single-chain Fv–Fc antibody fragments. Molecular Cancer Therapeutics, 5(6), 1550–1558.
40. Gauthier, M. A., & Klok, H. A. (2008). Peptide/protein-polymer conjugates: Synthetic strategies and design concepts. Chemical Communications (Cambridge, England), 23, 2591–2611.
41. Gébleux, R., & Casi, G. (2016). Antibody–drug conjugates: Current status and future perspectives. Pharmacology and Therapeutics, 167, 48–59.
42. Ghose, T. I., Huntley blair, A., & Kulkarni, P. N. (1983). Preparation of antibody-linked cytotoxic agents. Methods in Enzymology, 93, 280–333.
43. Glazer, A. N. (1970). Specific chemical modification of proteins. Annual Review of Biochemistry, 39, 101–130.
44. Goodman, L. S., & Wintrobe, M. M., et al. (1946). Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. Journal of the American Medical Association, 132, 126–132.
45. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., … Francisco, J. A. (2004). Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clinical Cancer Research, 10(20), 7063–7070.
46. Hughes, B. (2010). Antibody–drug conjugates for cancer: Poised to deliver? Nature Reviews. Drug Discovery, 9(9), 665–667.
47. Jaracz, S., Chen, J., Kuznetsova, L. V., & Ojima, I. (2005). Recent advances in tumor-targeting anticancer drug conjugates. Bioorganic and Medicinal Chemistry, 13(17), 5043–5054.
48. Jefferis, R. (2007). Antibody therapeutics: Isotype and glycoform selection. Expert Opinion on Biological Therapy, 7(9), 1401–1413.
49. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., … Mallet, W. (2008). Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnology, 26(8), 925–932.
50. Kalim, M., Chen, J., Wang, S., Lin, C., Ullah, S., Liang, K., … Zhan, J. B. (2017). Intracellular trafficking of new anticancer therapeutics: Antibody–drug conjugates. Drug Design, Development and Therapy, 11, 2265–2276.
51. Kato, Y., Tsukada, Y., Hara, T., & Hirai, H. (1983). Enhanced antitumor activity of mitomycin C conjugated with anti-alpha-fetoprotein antibody by a novel method of conjugation. Journal of Applied Biochemistry, 5(4-5), 313–319.
52. Katz, J., Janik, J. E., & Younes, A. (2011). Brentuximab vedotin (SGN-35). Clinical Cancer Research, 17(20), 6428–6436.
53. Kim, E. G., & Kim, K. M. (2015). Strategies and advancement in antibody–drug conjugate optimization for targeted cancer therapeutics. Biomolecules & Therapeutics (Seoul), 23(6), 493–509.
54. Kim, S. Y., Theunissen, J. W., Balibalos, J., Liao-Chan, S., Babcock, M. C., Wong, T., … Migone, T. S. (2015). A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood Cancer Journal, 5, e316.
55. Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497.
56. Kovtun, Y. V., & Goldmacher, V. S. (2007). Cell killing by antibody–drug conjugates. Cancer Letters, 255(2), 232–240.
57. Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., … Goldmacher, V. S. (2006). Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Research, 66(6), 3214–3221.
58. Lamb, Y. N. (2017). Inotuzumab ozogamicin: First global approval. Drugs, 77(14), 1603–1610.
59. Lambert, J. M. (2013). Drug-conjugated antibodies for the treatment of cancer. British Journal of Clinical Pharmacology, 76(2), 248–262.
60. Lambert, J. M., & Morris, C. Q. (2017). Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: A review. Advances in Therapy, 34(5), 1015–1035.
61. Lapusan, S., Vidriales, M. B., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., … Marie, J. P. (2012). Phase I studies of AVE9633, an anti-CD33 antibody–maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investigational New Drugs, 30(3), 1121–1131.
62. Law, C. L., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., … Wahl, A. F. (2004). Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clinical Cancer Research, 10(23), 7842–7851.
63. Lee, M. D., Manning, J. K., Williams, D. R., Kuck, N. A., Testa, R. T., & Borders, D. B. (1989). Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. The Journal of Antibiotics (Tokyo), 42(7), 1070–1087.
64. Lee, T. Y., Tjin Tham Sjin, R. M., Movahedi, S., Ahmed, B., Pravda, E. A., Lo, K. M., … Javaherian, K. (2008). Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clinical Cancer Research, 14(5), 1487–1493.
65. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., … Sliwkowski, M. X. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Research, 68(22), 9280–9290.
66. Liu, A. Y., Robinson, R. R., Hellstrom, K. E., Murray, E. D., Jr., Chang, C. P., & Hellstrom, I. (1987). Chimeric mouse–human IgG1 antibody that can mediate lysis of cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 84(10), 3439–3443.
67. McCombs, J. R., & Owen, S. C. (2015). Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry. AAPS Journal, 17(2), 339–351.
68. McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., … Carter, P. (2006). Engineered antibody–drug conjugates with defined sites and stoichiometries of drug attachment. Protein Engineering, Design & Selection: PEDS, 19(7), 299–307.
69. Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012). Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. Journal of the National Cancer Institute, 104(8), 622–634.
70. Moldoveanu, Z., Epps, J. M., Thorpe, S. R., & Mestecky, J. (1988). The sites of catabolism of murine monomeric IgA. Journal of Immunology, 141(1), 208–213.
71. Mullard, A. (2013). Maturing antibody–drug conjugate pipeline hits 30. Nature Reviews. Drug Discovery, 12(5), 329–332.
72. Niv, R., Cohen, C., Denkberg, G., Segal, D., & Reiter, Y. (2001). Antibody engineering for targeted therapy of cancer: Recombinant Fv-immunotoxins. Current Pharmaceutical Biotechnology, 2(1), 19–46.
73. Nolting, B. (2013). Linker technologies for antibody–drug conjugates. Methods in Molecular Biology, 1045, 71–100.
74. Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C. L., & Gerber, H. P. (2007). Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood, 110(13), 4370–4372.
75. Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., … Alley, S. C. (2010). Intracellular activation of SGN-35, a potent anti-CD30 antibody–drug conjugate. Clinical Cancer Research, 16(3), 888–897.
76. Panchal, R. G. (1998). Novel therapeutic strategies to selectively kill cancer cells. Biochemical Pharmacology, 55(3), 247–252.
77. Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014). Site-specific antibody drug conjugates for cancer therapy. mAbs, 6(1), 34–45.
78. Pereira, D. S., Guevara, C. I., Jin, L., Mbong, N., Verlinsky, A., Hsu, S. J., … Stover, D. R. (2015). AGS67E, an anti-CD37 monomethyl auristatin E antibody–drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: A new role for CD37 in AML. Molecular Cancer Therapeutics, 14(7), 1650–1660.
79. Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014). Antibody–drug conjugates: Current status and future directions. Drug Discovery Today, 19(7), 869–881.
80. Peters, C., & Brown, S. (2015). Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Reports, 35(4), e00225.
81. Pimm, M. V., Paul, M. A., Ogumuyiwa, Y., & Baldwin, R. W. (1988). Biodistribution and tumour localisation of a daunomycin–monoclonal antibody conjugate in nude mice with human tumour xenografts. Cancer Immunology and Immunotherapy, 27(3), 267–271.
82. Ravandi, F. (2011). Gemtuzumab ozogamicin: One size does not fit all—the case for personalized therapy. Journal of Clinical Oncology, 29(4), 349–351.
83. Ritchie, M., Tchistiakova, L., & Scott, N. (2013). Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs, 5(1), 13–21.
84. Rowland, A. J., Pietersz, G. A., & McKenzie, I. F. (1993). Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunology and Immunotherapy, 37(3), 195–202.
85. Salfeld, J. G. (2007). Isotype selection in antibody engineering. Nature Biotechnology, 25(12), 1369–1372.
86. Sapra, P., & Shor, B. (2013). Monoclonal antibody-based therapies in cancer: Advances and challenges. Pharmacology and Therapeutics, 138(3), 452–469.
87. Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006). Antibody targeted drugs as cancer therapeutics. Nature Reviews. Drug Discovery, 5(2), 147–159.
88. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C., Jr. (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Research, 45(2), 879–885.
89. Schwartz, R. S. (2004). Paul Ehrlich's magic bullets. New England Journal of Medicine, 350(11), 1079–1080.
90. Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews Cancer, 12(4), 278–287.
91. Senter, P. D. (2009). Potent antibody drug conjugates for cancer therapy. Current Opinion in Chemical Biology, 13(3), 235–244.
92. Senter, P. D., & Sievers, E. L. (2012). The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology, 30(7), 631–637.
93. Shefet-Carasso, L., & Benhar, I. (2015). Antibody-targeted drugs and drug resistance—challenges and solutions. Drug Resistance Updates, 18, 36–46.
94. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., … Junutula, J. R. (2012). Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates. Nature Biotechnology, 30(2), 184–189.
95. Shor, B., Kahler, J., Dougher, M., Xu, J., Mack, M., Rosfjord, E., … Sapra, P. (2016). Enhanced antitumor activity of an anti-5T4 antibody–drug conjugate in combination with PI3K/mTOR inhibitors or taxanes. Clinical Cancer Research, 22(2), 383–394.
96. Sievers, E. L., & Linenberger, M. (2001). Mylotarg: Antibody-targeted chemotherapy comes of age. Current Opinion in Oncology, 13(6), 522–527.
97. Sievers, E. L., & Senter, P. D. (2013). Antibody–drug conjugates in cancer therapy. Annual Review of Medicine, 64, 15–29.
98. Sletten, E. M., & Bertozzi, C. R. (2009). Bioorthogonal chemistry: Fishing for selectivity in a sea of functionality. Angewandte Chemie (International Edition in English), 48(38), 6974–6998.
99. Smets, L. A. (1994). Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs, 5(1), 3–9.
100. Smith, L. M., Nesterova, A., Alley, S. C., Torgov, M. Y., & Carter, P. J. (2006). Potent cytotoxicity of an auristatin-containing antibody–drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Molecular Cancer Therapeutics, 5(6), 1474–1482.
101. Smyth, M. J., Pietersz, G. A., & McKenzie, I. F. (1987). Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. Cancer Research, 47(1), 62–69.
102. Sondergeld, P., van de Donk, N. W., Richardson, P. G., & Plesner, T. (2015). Monoclonal antibodies in myeloma. Clinical Advances in Hematology & Oncology, 13(9), 599–609.
103. Spearman, M. E., Goodwin, R. M., Apelgren, L. D., & Bumol, T. F. (1987). Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. Journal of Pharmacology and Experimental Therapeutics, 241(2), 695–703.
104. Staudacher, A. H., & Brown, M. P. (2017). Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required? British Journal of Cancer, 117(12), 1736–1742.
105. Strome, S. E., Sausville, E. A., & Mann, D. (2007). A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist, 12(9), 1084–1095.
106. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., … Alley, S. C. (2005). Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chemistry, 16(5), 1282–1290.
107. Teicher, B. A., & Chari, R. V. (2011). Antibody conjugate therapeutics: Challenges and potential. Clinical Cancer Research, 17(20), 6389–6397.
108. ter Weele, E. J., Van scheltinga, A. G., Kosterink, J. G., Pot, L., Vedelaar, S. R., Lamberts, L. E., … de Vries, E. G. (2015). Imaging the distribution of an antibody–drug conjugate constituent targeting mesothelin with (8)(9)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget, 6(39), 42081–42090.
109. Thorson, J., Sievers, E., Ahlert, J., Shepard, E., Whitwam, R., Onwueme, K., & Ruppen, M. (2000). Understanding and exploiting nature's chemical arsenal: The past, present and future of calicheamicin research. Current Pharmaceutical Design, 6(18), 1841–1879.
110. Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008). Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews, 60(12), 1421–1434.
111. Trail, P., Willner, D., Lasch, S., Henderson, A., Hofstead, S., Casazza, A., … Hellstrom, K. (1993). Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science, 261(5118), 212–215.
112. Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., … Strohl, W. R. (2014). An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods, 65(1), 114–126.
113. van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martinez-Martinez, P., Vermeulen, E., … Parren, P. W. (2007). Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science, 317(5844), 1554–1557.
114. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., … Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367(19), 1783–1791.
115. Wagner-Rousset, E., Janin-Bussat, M. C., Colas, O., Excoffier, M., Ayoub, D., Haeuw, J. F., … Beck, A. (2014). Antibody–drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. mAbs, 6(1), 173–184.
116. Walter, R. B. (2005). Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood, 105(3), 1295–1302.
117. Wang, Y., Tian, Z., Thirumalai, D., & Zhang, X. (2014). Neonatal Fc receptor (FcRn): A novel target for therapeutic antibodies and antibody engineering. Journal of Drug Targeting, 22(4), 269–278.
118. Wei, C., Zhang, G., Clark, T., Barletta, F., Tumey, L. N., Rago, B., … Han, X. (2016). Where did the linker–payload go? A quantitative investigation on the destination of the released linker–payload from an antibody–drug conjugate with a maleimide linker in plasma. Analytical Chemistry, 88(9), 4979–4986.
119. Wiggins, B., Liu-Shin, L., Yamaguchi, H., & Ratnaswamy, G. (2015). Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody–drug conjugates. Journal of Pharmaceutical Sciences, 104(4), 1362–1372.
120. Yoo, E. M., Wims, L. A., Chan, L. A., & Morrison, S. L. (2003). Human IgG2 can form covalent dimers. Journal of Immunology, 170(6), 3134–3138.
121. Zhang, A., Fang, J., Chou, R. Y., Bondarenko, P. V., & Zhang, Z. (2015). Conformational difference in human IgG2 disulfide isoforms revealed by hydrogen/deuterium exchange mass spectrometry. Biochemistry, 54(10), 1956–1962.